In-Kyung Sung

In-Kyung Sung

Auto-generated profile, based on publicly available information

In-Kyung Sung

Department of Internal Medicine Konkuk University School of Medicine Seoul South Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2015 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
SLSang Pyo Lee
Sang Pyo Lee
ISIn-Kyung Sung
In-Kyung Sung
JKJeong Hwan Kim
Jeong Hwan Kim
SLSun-Young Lee
Sun-Young Lee
HPHyung Seok Park
Hyung Seok Park
CSChan Sup Shim
Chan Sup Shim
Sang Pyo Lee, In-Kyung Sung,* Jeong Hwan Kim, Sun-Young Lee, Hyung Seok Park, and Chan Sup Shim. J Neurogastroenterol Motil 1999;0:. http://dx.doi.org/10.5056/jnm14116

31 October 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
YCYu Kyung Kyung Cho
Yu Kyung Kyung Cho
JKJae Hak Kim
Jae Hak Kim
TKTae-Oh Kim
Tae-Oh Kim
JOJUNG HWAN OH
JUNG HWAN OH
SCSuck Chei Choi
Suck Chei Choi
YLYong Chan Lee
Yong Chan Lee
SUMMARY: Background: Tegoprazan is a novel potassium‐competitive acid blocker used to treat acid‐related disorders.Aim: To compare tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis (EE)Methods: In this phase 3, double‐blind, multi‐centre study, patients with endoscopically confirmed healed EE were randomised 1:1 to receive tegoprazan 25 mg or lansoprazole 15 mg once daily for up to 24 weeks. The primary efficacy endpoint was the endoscopic remission rate after 24 weeks. The secondary efficacy endpoint was the endoscopic remission rate after 12 weeks. Safety endpoints included adverse events, clinical laboratory results and serum gastrin and pepsinogen I/II levels.Results: We randomised patients to tegoprazan 25 mg (n = 174) or lansoprazole 15 mg (n = 177). Most had mild EE (Los Angeles (LA) grade A: 57.3%, LA grade B: 37.3%). The endoscopic remission rate after 24 weeks was 90.6% with tegoprazan and 89.5% with lansoprazole. Tegoprazan was not inferior to lansoprazole for maintaining endoscopic remission at 24 weeks and 12 weeks. In subgroup analysis, tegoprazan 25 mg showed no significant difference in maintenance rate according to LA grade (p = 0.47). The maintenance effect of tegoprazan was consistent in CYP2C19 extensive metabolisers (p = 0.76). Increases in serum gastrin were not higher in tegoprazan‐treated than lansoprazole‐treated patients.Conclusions: Tegoprazan 25 mg was non‐inferior to lansoprazole 15 mg in maintenance of healing of mild EE. In this study, tegoprazan had a similar safety profile to lansoprazole.

30 November 2017 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
SLSang Pyo Lee
Sang Pyo Lee
ISIn-Kyung Sung
In-Kyung Sung
JKJeong Hwan Kim
Jeong Hwan Kim
SLSun-Young Lee
Sun-Young Lee
HPHyung Seok Park
Hyung Seok Park
CSChan Sup Shim
Chan Sup Shim
Peptic ulcer disease (PUD) is a common condition, but is difficult to detect in asymptomatic individuals. We aimed to investigate the prevalence of symptomatic and asymptomatic PUD during screening endoscopy and to identify risk factors for the presence of symptoms in patients with PUD. We investigated subjects who underwent a health inspection, including endoscopy of the upper gastrointestinal (GI) tract and a serum anti-Helicobacter pylori IgG assay, and who completed a self-report questionnaire about their symptoms. Of the 12,852 subjects included in the study, 124 (1.0%) had symptomatic PUD and 309 (2.4%) had asymptomatic PUD. Old age, current smoking, and H. pylori infection were independent risk factors for symptomatic and asymptomatic PUD. Use of non-steroidal anti-inflammatory drugs (NSAIDs) was an independent risk factor only for symptomatic PUD (p=0.040). Compared to subjects with asymptomatic PUD, subjects with symptomatic PUD were more likely to have active-stage ulcers (p=0.002) and to drink more heavily (p=0.005). Use of NSAIDs is a risk factor for symptomatic PUD, but not for asymptomatic PUD. Excessive alcohol consumption and active-stage ulcers in patients with PUD are related to the presence of gastroduodenal symptoms.

1 August 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SLSang Pyo Lee
Sang Pyo Lee
ISIn-Kyung Sung
In-Kyung Sung
JKJeong Hwan Kim
Jeong Hwan Kim
SLSun-Young Lee
Sun-Young Lee
HPHyung Seok Park
Hyung Seok Park
HKHyun Kyun Ki
Hyun Kyun Ki

30 April 2025 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
YCYonghoon Choi
Yonghoon Choi
YYYoung-Hoon Youn
Young-Hoon Youn
SKSeung Joo Kang
Seung Joo Kang
JSJeong Eun Shin
Jeong Eun Shin
YCYoung Sin Cho
Young Sin Cho
TMThe Korean Society Of Neurogastroenterology And Motility
The Korean Society Of Neurogastroenterology And Motility
Yonghoon Choi, Young Hoon Youn, Seung Joo Kang, Jeong Eun Shin, Young Sin Cho, Yoon Suk Jung, Seung Yong Shin, Cheal Wung Huh, Yoo Jin Lee, Hoon Sup Koo, Kwangwoo Nam, Hong Sub Lee, Dong Hyun Kim, Ye Hyun Park, Min Cheol Kim, Hyo Yeop Song, Sung-Hoon Yoon, Sang Yeol Lee, Miyoung Choi, Moo-In Park, and In-Kyung Sung; the Korean Society of Neurogastroenterology and Motility. J Neurogastroenterol Motil 2025;31:133-69. https://doi.org/10.5056/jnm25007

15 January 2015 in Gut and Liver
Verified
Journal Article
Open access
SLSang Pyo Lee
Sang Pyo Lee
ISIn-Kyung Sung
In-Kyung Sung
JKJeong Hwan Kim
Jeong Hwan Kim
SLSun-Young Lee
Sun-Young Lee
HPHyung Seok Park
Hyung Seok Park
CSChan Sup Shim
Chan Sup Shim
Colonoscopic polypectomy is highly efficient in preventing colorectal cancer, but polyps may not always be completely removed. Improved knowledge of the risk factors for incomplete polyp resection after polypectomy may decrease the cancer risk and additional costs. The aim of this study was to investigate the conditions that can cause incomplete polyp resection (IPR) after colonoscopic polypectomy. A total of 12,970 polyps that were removed by colonoscopic polypectomy were investigated. Among them, we identified 228 cases with a positive resection mar-gin and 228 controls with a clear resection margin that were matched for age, gender, and polyp size. We investigated the location, morphology, and histological type of the polyps and evaluated the skills of the endoscopist and assisting nurse. Multivariate analysis revealed that the polyps, which were located in the proximal part of the colon and rectum, were at significant risk of IPR. Histologically, an advanced polyp and an inexperienced assistant were also independent risk factors for IPR. Polypectomy should be performed more carefully for polyps suspected to be cancerous and polyps located in the proximal part of the colon or rectum. A systematic training program for inexperienced assistants may be needed to decrease the risk of IPR.